Analyst Expectations for Arcutis Biotherapeutics's Future
Portfolio Pulse from Benzinga Insights
Arcutis Biotherapeutics (NASDAQ:ARQT) has received a mix of bullish and indifferent ratings from analysts in the last quarter. The average price target is $34.83, which is significantly higher than the current price of $3.3701. However, this target represents a 28.19% decrease from the previous average price target of $48.50.
October 13, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Arcutis Biotherapeutics has received mixed analyst ratings, with a lower average price target than before.
The mixed analyst ratings indicate uncertainty about the company's future performance. The lower average price target suggests that analysts have lowered their expectations for the stock, which could potentially impact investor sentiment and the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100